Pfizer Recollects One other Blood Strain Treatment

April 25, 2022

The pharmaceutical firm Pfizer has voluntary recalled a blood strain medicine for the second time in a month.

Pfizer is recalling 5 numerous blood strain medication Accupril due to elevated ranges of a nitrosamine, Nnitroso-quinapril, the corporate mentioned in a information launch posted Friday on the FDA web site.

Nitrosamines are present in water and meals, together with grilled meats and dairy merchandise, however impurities could improve an individual’s most cancers threat over lengthy intervals of time, Pfizer mentioned.

Accupril is used to decrease blood strain and handle coronary heart failure. Pfizer mentioned it has not acquired any experiences of adversarial reactions by folks taking the drug.

“Pfizer believes the profit/threat profile of the merchandise stays constructive primarily based on at present accessible knowledge. Though long-term ingestion of Nnitroso-quinapril could also be related to a possible elevated most cancers threat in people, there is no such thing as a rapid threat to sufferers taking this medicine,” the corporate mentioned.

The Accupril tables are bought in 10-, 20- and 40-mg doses. The affected lot numbers are DR9639, DX8682, DG1188, DX6031, and CK6260.

Sufferers taking the product ought to speak to their physician. Sufferers with the affected product ought to name 888-345-0481.

Pfizer recalled one other blood strain medicine on March 22.

The affected merchandise in that recall are quinapril HCl/hydrochlorothiazide (Accuretic) tablets that Pfizer distributes, and two licensed generics, quinapril plus hydrochlorothiazide and quinapril HCl/hydrochlorothiazide, distributed by Greenstone. The recall is over greater than accepted ranges of N-nitroso-quinapril, a compound referred to as a nitrosamine.

We will be happy to hear your thoughts

Leave a reply

Electronic Vault
Enable registration in settings - general
Compare items
  • Total (0)